Loading
A phase 1 trial of AB-205 run by Angiocrine Bioscience, completed.
Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation is a phase 1 interventional study registered as NCT03925935 by Angiocrine Bioscience, with 42 participants enrolled, started 2019-05-07. Conditions recorded: Hodgkin Lymphoma and Non-hodgkin Lymphoma. Interventions recorded: AB-205.
Shares AB-205, Angiocrine Bioscience, Hodgkin lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Hodgkin lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Hodgkin lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/